What the trial was testing
The Effisayil-1 enrolled 53 patients with generalized pustular psoriasis. The study was sponsored by Boehringer Ingelheim and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
54% had no visible pustules within one week of a single IV dose.
New England Journal of Medicine · 2021 · NCT03782792
These findings — that of patients had no visible pustules at week 1 with spesolimab vs. placebo — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 53 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with generalized pustular psoriasis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Spesolimab (Spevigo) is FDA-approved for treating flares of generalized pustular psoriasis in adults and available now. It is given as a single IV infusion at the start of a flare, with the option to repeat. Ask your dermatologist or hospital team if you have a history of GPP flares.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open generalized pustular psoriasis trials
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
International Rare And Severe Psoriasis Expert Network
This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.